GO:0034370 triglyceride-rich lipoprotein particle remodeling: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0034370 describes the acquisition, loss, or modification of proteins and lipids within triglyceride-rich lipoprotein particles, including lipolytic and lipid-transfer reactions.
• Triglyceride-rich lipoprotein remodeling is central to the metabolism of chylomicrons and VLDL and determines the formation of atherogenic remnant particles.
• Key enzymes and transfer proteins include LPL, CETP, APOC2, APOC3, APOA5, and APOE, which together regulate lipolysis and lipid exchange.
• Remodeling products, especially cholesterol-enriched remnants, are causally linked to atherosclerotic cardiovascular disease.
• Therapeutic strategies targeting APOC3, ANGPTL3, and CETP are being developed to reduce remnant cholesterol and cardiovascular risk.
• CRISPR-based knockout, point-mutation, knock-in, and overexpression models enable causal dissection of remodeling genes in hepatocytes and macrophages.
Description
Triglyceride-rich lipoprotein particle remodeling (GO:0034370) is the biological process by which triglyceride-rich lipoproteins such as chylomicrons and very-low-density lipoproteins (VLDL) undergo changes in their protein and lipid composition. This process includes the hydrolysis of core triglycerides by lipoprotein lipase (LPL), the loss of free fatty acids, and the cholesteryl ester transfer protein (CETP)-mediated exchange of cholesteryl esters from HDL for triglycerides from triglyceride-rich lipoproteins. The remodeling reactions convert large, triglyceride-rich particles into smaller, cholesterol-enriched remnant lipoproteins that are increasingly recognized as causal contributors to atherosclerotic cardiovascular disease. For researchers, GO:0034370 provides a defined ontological framework to study how genetic and pharmacological perturbations alter lipoprotein metabolism. Genome-wide association and proteomic studies have linked apolipoprotein B-containing lipoproteins and their remodeling to distinct atherosclerotic risk profiles. The process is also a target for emerging therapies, including APOC3 and ANGPTL3 inhibition, which lower remnant cholesterol and cardiovascular events. Understanding the molecular players and regulatory nodes of triglyceride-rich lipoprotein remodeling is therefore essential for both mechanistic biology and therapeutic development.
triglyceride-rich lipoprotein particle remodeling At A Glance
| GO ID | GO:0034370 |
|---|---|
| GO term | triglyceride-rich lipoprotein particle remodeling |
| Ontology | biological_process |
| Synonym | triacylglycerol-rich lipoprotein particle remodeling; triacylglycerol-rich lipoprotein particle remodelling; triglyceride-rich lipoprotein particle remodelling |
| Major function | Hydrolysis of triglycerides by lipoprotein lipase and CETP-mediated exchange of cholesteryl esters and triglycerides, leading to remnant lipoprotein formation |
| Key enzymes | Lipoprotein lipase (LPL), cholesteryl ester transfer protein (CETP), hepatic lipase (LIPC) |
| Key apolipoproteins | APOB, APOC2, APOC3, APOA5, APOE |
| Cellular location | Plasma and extracellular space; particle remodeling occurs in the circulation |
| Disease relevance | Atherosclerotic cardiovascular disease, hypertriglyceridemia, metabolic syndrome |
What Is GO:0034370?
In our own words, GO:0034370 encompasses all reactions that change the protein or lipid content of a triglyceride-rich lipoprotein particle. This includes the LPL-mediated hydrolysis of triglycerides with release of free fatty acids, and the CETP-mediated transfer of cholesteryl esters into the particle with simultaneous transfer of triglycerides out of the particle. The term also covers modifications in apolipoprotein composition that accompany these lipid changes, such as the loss or gain of APOE and APOC proteins.
Why Is triglyceride-rich lipoprotein particle remodeling Important in Cell Biology?
Triglyceride-rich lipoprotein particle remodeling is important because it determines the fate of dietary and hepatic lipids and directly influences the formation of atherogenic remnant particles. Remnant cholesterol carried by these particles is a causal risk factor for atherosclerotic cardiovascular disease, independent of LDL cholesterol. The process also modulates postprandial lipemia and is a target for lipid-lowering therapies such as APOC3 inhibitors and CETP modulators.
• Controls the conversion of chylomicrons and VLDL into remnant lipoproteins that are taken up by the liver or deposited in arteries.
• Determines plasma triglyceride and remnant cholesterol levels, which are independent cardiovascular risk factors.
• Regulates postprandial lipid metabolism and the duration of postprandial lipemia.
• Provides a mechanistic link between insulin resistance, type 2 diabetes, and dyslipidemia.
• Is a target for emerging therapeutics including APOC3, ANGPTL3, and CETP inhibitors.
• Influences LDL heterogeneity and the generation of small dense LDL particles.
• Modulates HDL metabolism through CETP-mediated lipid exchange.
• Affects macrophage foam cell formation and atherosclerosis progression.
What Happens During triglyceride-rich lipoprotein particle remodeling?
Lipolysis of core triglycerides by lipoprotein lipase
In simple terms: Lipoprotein lipase acts like a molecular scissors that cuts triglycerides inside large fat-carrying particles, releasing free fatty acids.
The first major step in triglyceride-rich lipoprotein remodeling is the hydrolysis of core triglycerides by lipoprotein lipase (LPL) anchored to the capillary endothelium via heparan sulfate proteoglycans and GPIHBP1. LPL requires APOC2 as an essential cofactor for full activity, while APOC3 and ANGPTL proteins inhibit LPL. This lipolytic step releases free fatty acids for tissue uptake and shrinks the particle, generating smaller remnant lipoproteins.
CETP-mediated lipid exchange
In simple terms: CETP acts like a lipid swap meet, moving cholesterol from HDL into triglyceride-rich particles while moving triglycerides in the opposite direction.
Cholesteryl ester transfer protein (CETP) mediates the transfer of cholesteryl esters from HDL to triglyceride-rich lipoproteins, with simultaneous transfer of triglycerides from triglyceride-rich lipoproteins to HDL. This exchange enriches remnant particles with cholesterol and depletes them of triglycerides, contributing to the atherogenic profile of remnants. Statin therapy has been shown to reduce CETP-mediated remodeling of triglyceride-rich lipoprotein subspecies in type IIb hyperlipidemia.
Apolipoprotein remodeling and particle maturation
In simple terms: The protein coat of the particle changes as it shrinks, which affects how the particle is recognized by receptors.
During remodeling, the apolipoprotein composition of triglyceride-rich lipoproteins changes. APOE and APOC proteins are exchanged between particles and HDL, influencing receptor-mediated clearance. APOA5 reduces VLDL clearance by altering APOE content, thereby modulating remnant uptake. These apolipoprotein changes determine whether the particle is cleared by hepatic receptors or retained in circulation.
Formation of remnant lipoproteins
In simple terms: After losing triglycerides and gaining cholesterol, the particle becomes a remnant that can clog arteries.
The end product of triglyceride-rich lipoprotein remodeling is the remnant lipoprotein, a cholesterol-enriched particle that is smaller than its precursor. Remnants can be taken up by the liver via LDL receptor and LRP1, but when present in excess they penetrate the arterial wall and promote atherosclerosis. Elevated remnant cholesterol is a causal risk factor for cardiovascular disease.
Regulation by apolipoproteins and angiopoietin-like proteins
In simple terms: Several proteins act as brakes or accelerators on the remodeling process.
APOC3 inhibits LPL and hepatic lipase, slowing triglyceride hydrolysis and increasing plasma triglycerides. ANGPTL3, ANGPTL4, and ANGPTL8 regulate LPL activity in a tissue-specific manner. APOA5 modulates LPL activity and VLDL clearance. These regulators are targets for therapeutic intervention to lower remnant cholesterol.
Key Genes Involved in GO:0034370 triglyceride-rich lipoprotein particle remodeling
The following genes encode proteins that directly participate in or regulate triglyceride-rich lipoprotein particle remodeling.
| Gene | Major Role | Research Relevance |
|---|---|---|
| LPL | Hydrolyzes core triglycerides in chylomicrons and VLDL | Rate-limiting enzyme; target for hypertriglyceridemia research |
| CETP | Mediates cholesteryl ester/triglyceride exchange between HDL and TRLs | Modulates remnant cholesterol; drug target |
| APOC2 | Essential cofactor for LPL activity | Deficiency causes hypertriglyceridemia |
| APOC3 | Inhibits LPL and hepatic lipase | Therapeutic target; antisense inhibitors in trials |
| APOA5 | Modulates LPL activity and VLDL clearance | Genetic variants affect triglyceride levels |
| APOE | Ligand for hepatic receptor uptake of remnants | Isoforms affect remnant clearance and Alzheimer risk |
| LIPC | Hepatic lipase; hydrolyzes triglycerides and phospholipids in remnants | Modulates remnant and HDL metabolism |
| ANGPTL3 | Inhibits LPL and endothelial lipase | Target for evinacumab and siRNA therapies |
| ANGPTL4 | Inhibits LPL in adipose and muscle | Regulates tissue-specific lipid uptake |
| ANGPTL8 | Regulates ANGPTL3 activity | Modulates plasma triglycerides |
| APOB | Structural protein of VLDL and chylomicrons | Proteomic profiling links APOB particles to atherosclerosis |
| GPIHBP1 | Endothelial platform for LPL | Mutations cause chylomicronemia |
| LMF1 | Lipase maturation factor 1 | Required for LPL folding and activity |
| APOA1 | Major HDL apolipoprotein; acceptor in CETP reactions | Modulates reverse cholesterol transport |
| SCARB1 | HDL receptor; influences CETP-mediated remodeling | Affects HDL and remnant metabolism |
| LRP1 | Remnant receptor | Mediates hepatic clearance of remnants |
| LDLR | Clearance of remnant and LDL particles | Statin target; mutations cause familial hypercholesterolemia |
| CREB3L3 | Transcription factor regulating lipogenic genes | Modulates VLDL secretion and remodeling |
How Is triglyceride-rich lipoprotein particle remodeling Regulated?
Triglyceride-rich lipoprotein particle remodeling is regulated at multiple levels. Transcriptionally, CREB3L3 and SREBP-1c control the expression of LPL, APOC2, and APOA5. Post-translationally, ANGPTL3, ANGPTL4, and ANGPTL8 inhibit LPL in a tissue-specific manner, while APOC3 acts as a non-competitive inhibitor. Hormonal signals such as insulin promote LPL activity in adipose tissue and suppress it in muscle, linking remodeling to metabolic state. CETP activity is regulated by its plasma concentration and by the lipid composition of donor and acceptor particles. Therapeutic modulation of these regulators, including APOC3 and ANGPTL3 inhibition, directly alters remodeling flux and remnant cholesterol levels.
triglyceride-rich lipoprotein particle remodeling and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| LPL | Hypertriglyceridemia, chylomicronemia | Hepatocyte or macrophage KO; LPL overexpression |
| APOC3 | Hypertriglyceridemia, cardiovascular risk | KO and point-mutation models; antisense validation |
| CETP | Atherosclerosis, remnant cholesterol | CETP knockout and humanized knock-in models |
| APOA5 | Hypertriglyceridemia | KO and overexpression in hepatocytes |
| APOE | Remnant clearance, Alzheimer risk | APOE isoform knock-in mice; KO models |
Atherosclerotic cardiovascular disease
Remnant lipoproteins generated by triglyceride-rich lipoprotein remodeling are causally linked to atherosclerotic cardiovascular disease. Elevated remnant cholesterol is an independent risk factor, and proteomic profiling of apolipoprotein B-containing lipoproteins reveals distinct roles in atherosclerosis. Therapies that enhance remodeling or reduce remnant production lower cardiovascular events.
Hypertriglyceridemia and chylomicronemia
Defects in LPL, APOC2, APOA5, GPIHBP1, or LMF1 cause severe hypertriglyceridemia and chylomicronemia due to impaired triglyceride-rich lipoprotein remodeling. APOC3 gain-of-function variants raise triglycerides, while loss-of-function variants lower them and reduce cardiovascular risk.
Metabolic syndrome and type 2 diabetes
Insulin resistance increases hepatic VLDL secretion and impairs LPL activity, leading to overproduction of triglyceride-rich lipoproteins and enhanced CETP-mediated remodeling. This contributes to the atherogenic dyslipidemia of metabolic syndrome.
LDL heterogeneity and small dense LDL
CETP-mediated remodeling of triglyceride-rich lipoproteins contributes to the formation of small dense LDL particles, which are more atherogenic. The metabolic origins of LDL heterogeneity are closely tied to triglyceride-rich lipoprotein remodeling.
From triglyceride-rich lipoprotein particle remodeling-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of APOC3 enhance LPL-mediated remodeling? | APOC3 knockout hepatocyte cell line |
| Does a point mutation in LPL alter catalytic activity? | LPL point-mutation knock-in via CRISPR |
| How does CETP expression affect remnant cholesterol? | CETP overexpression in hepatic cells |
| What is the role of APOA5 in VLDL clearance? | APOA5 knockout and tagged knock-in models |
| Can a candidate gene regulate LPL activity? | CRISPR library screening in hepatocytes |
| Does APOE isoform affect remnant uptake? | APOE isoform knock-in in iPSC-derived hepatocytes |
How to Study the triglyceride-rich lipoprotein particle remodeling Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Lipidomics | Triglyceride and cholesteryl ester content | Quantify remodeling products |
| CRISPR knockout screening | Gene requirement for remodeling | Identify novel regulators |
| Proteomic profiling | Apolipoprotein composition | Link APOB particles to atherosclerosis |
| Stable isotope kinetics | Remodeling flux in vivo | Assess therapy effects |
| CETP activity assay | Cholesteryl ester transfer rate | Evaluate CETP modulators |
| LPL activity assay | Triglyceride hydrolysis rate | Measure enzyme function |
| Remnant cholesterol assay | Remnant particle concentration | Cardiovascular risk assessment |
Lipoprotein profiling and lipidomics
Mass spectrometry-based lipidomics and lipoprotein fractionation can quantify triglyceride and cholesteryl ester content in triglyceride-rich lipoproteins and their remnants. These methods measure the net effect of remodeling reactions and are used to assess genetic or pharmacological perturbations.
CRISPR screening and functional genomics
Genome-wide CRISPR knockout screens in hepatocyte cell lines can identify genes that regulate LPL activity, CETP expression, or remnant uptake. Candidate hits are validated by targeted knockout or overexpression.
Proteomic profiling of apolipoprotein B-containing lipoproteins
Plasma proteomic profiling of apolipoprotein B-containing lipoproteins reveals distinct roles in atherosclerosis and can identify remodeling-related protein signatures. This approach links molecular changes to cardiovascular risk.
In vivo models and tracer studies
Stable isotope tracer studies in humans and animal models measure the kinetics of triglyceride-rich lipoprotein remodeling and remnant clearance. These methods are used to evaluate therapeutic interventions targeting APOC3, ANGPTL3, or CETP.
How CRISPR Can Be Used to Study GO:0034370 triglyceride-rich lipoprotein particle remodeling
Knockout
CRISPR knockout of genes such as APOC3, CETP, or LPL in hepatocyte cell lines can reveal their causal role in triglyceride-rich lipoprotein remodeling. Knockout models are used to validate targets identified by genome-wide screens.
Point Mutation
Point mutations in LPL, APOA5, or APOE can be introduced to mimic human variants associated with hypertriglyceridemia or altered remnant clearance. These models help dissect structure-function relationships.
Knock-in
Knock-in of human APOE isoforms or CETP into mouse models enables study of human-specific remodeling pathways. Tagged knock-in allows tracking of apolipoprotein trafficking.
Overexpression
Overexpression of APOC3, ANGPTL3, or CETP in cell lines or animal models can drive remodeling changes and test therapeutic inhibitors. Overexpression models are used to assess dose-dependent effects on remnant cholesterol.
How EDITGENE Supports triglyceride-rich lipoprotein particle remodeling Research
Researchers studying triglyceride-rich lipoprotein particle remodeling-related genes often need to determine whether a candidate gene is causally involved in lipid metabolism or is merely a biomarker. EDITGENE provides CRISPR-based cell models and screening services to enable such causal studies.
Contact EDITGENE today to design your custom CRISPR model for triglyceride-rich lipoprotein particle remodeling research.
Frequently Asked Questions About triglyceride-rich lipoprotein particle remodeling
What is triglyceride-rich lipoprotein particle remodeling?
It is the biological process (GO:0034370) by which triglyceride-rich lipoproteins such as chylomicrons and VLDL change their lipid and protein composition through lipolysis and lipid transfer.
What genes are involved in triglyceride-rich lipoprotein particle remodeling?
Key genes include LPL, CETP, APOC2, APOC3, APOA5, APOE, LIPC, ANGPTL3, ANGPTL4, and APOB.
How does CETP contribute to triglyceride-rich lipoprotein remodeling?
CETP transfers cholesteryl esters from HDL to triglyceride-rich lipoproteins and triglycerides in the opposite direction, enriching remnants with cholesterol.
What is the role of lipoprotein lipase in this process?
LPL hydrolyzes core triglycerides in chylomicrons and VLDL, releasing free fatty acids and shrinking the particles into remnants.
Why is triglyceride-rich lipoprotein remodeling important for heart disease?
Remnant lipoproteins produced by remodeling are causally linked to atherosclerotic cardiovascular disease.
What diseases are associated with defects in triglyceride-rich lipoprotein remodeling?
Hypertriglyceridemia, chylomicronemia, metabolic syndrome, and atherosclerotic cardiovascular disease.
How can CRISPR be used to study triglyceride-rich lipoprotein remodeling?
CRISPR knockout, point mutation, knock-in, and overexpression models can test the causal role of genes like APOC3, CETP, and LPL.
What are the therapeutic targets in triglyceride-rich lipoprotein remodeling?
APOC3, ANGPTL3, CETP, and APOA5 are targets for emerging therapies to lower remnant cholesterol.
What methods measure triglyceride-rich lipoprotein remodeling?
Lipidomics, lipoprotein fractionation, stable isotope kinetics, and CETP/LPL activity assays.
What is the difference between triglyceride-rich lipoprotein remodeling and remnant formation?
Remodeling is the process; remnant formation is the resulting particle state after lipolysis and lipid exchange.
Conclusion
GO:0034370 triglyceride-rich lipoprotein particle remodeling is a central metabolic process that converts large triglyceride-rich lipoproteins into cholesterol-enriched remnants. Its molecular players, including LPL, CETP, APOC3, and APOA5, are validated therapeutic targets for cardiovascular disease. CRISPR-based models provide powerful tools to dissect the causal roles of these genes and to accelerate the development of remnant-lowering therapies.
References
- 1. Ginsberg HN et al.. 2021. Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society.. Eur Heart J 42(47):4791-4806 PMID: 34472586
- 2. Duran EK et al.. 2021. Triglyceride-Rich Lipoprotein Remnants and Cardiovascular Disease.. Clin Chem 67(1):183-196 PMID: 33409533
- 3. Morze J et al.. 2026. Apolipoprotein B-containing lipoproteins: distinct roles in atherosclerosis revealed by plasma proteomic profiling.. Eur Heart J PMID: 42671122
- 4. Dallinga-Thie GM et al.. 2016. Triglyceride-Rich Lipoproteins and Remnants: Targets for Therapy?. Curr Cardiol Rep 18(7):67 PMID: 27216847
- 5. Chapman MJ et al.. 2025. Triglyceride-rich lipoproteins, remnants and atherosclerotic cardiovascular disease: What we know and what we need to know.. Atherosclerosis 410:120529 PMID: 41202476
- 6. Tarapore P et al.. 2025. Apolipoprotein A5 reduces clearance of VLDL by altering apolipoprotein E content.. J Lipid Res 66(11):100917 PMID: 41043689
- 7. Guerin M et al.. 2002. Atorvastatin reduces postprandial accumulation and cholesteryl ester transfer protein-mediated remodeling of triglyceride-rich lipoprotein subspecies in type IIb hyperlipidemia.. J Clin Endocrinol Metab 87(11):4991-5000 PMID: 12414863
- 8. Berneis KK et al.. 2002. Metabolic origins and clinical significance of LDL heterogeneity.. J Lipid Res 43(9):1363-79 PMID: 12235168
